We are live on
!
Find out more
VanEck Associates Portfolio holdings
AUM
$133B
1-Year Est. Return
72.99%
This Fund
S&P 500
This Quarter
Est. Return
+4.01%
1 Year Est. Return
+72.99%
3 Year Est. Return
+157.94%
5 Year Est. Return
+206.35%
10 Year Est. Return
+770.56%
AUM
$21.4B
AUM Growth
+$1.27B
(+6.3%)
Cap. Flow
+$730M
Cap. Flow
% of AUM
3.41%
Top 10 Holdings %
Top 10 Hldgs %
26.79%
Holding
881
New
137
Increased
443
Reduced
202
Closed
30
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AngloGold Ashanti
AU
|
+$259M |
| 2 |
Vale
VALE
|
+$83M |
| 3 |
WPX
WPX Energy, Inc.
WPX
|
+$44.4M |
| 4 |
Gold Fields
GFI
|
+$39.7M |
| 5 |
Royal Gold
RGLD
|
+$35.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MON
Monsanto Co
MON
|
+$109M |
| 2 |
Newmont
NEM
|
+$96M |
| 3 |
B
Barrick Mining
B
|
+$77.1M |
| 4 |
Franco-Nevada
FNV
|
+$63.2M |
| 5 |
GG
Goldcorp Inc
GG
|
+$58M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Materials | 50.75% |
| 2 | Energy | 16.94% |
| 3 | Healthcare | 6.45% |
| 4 | Technology | 5.96% |
| 5 | Consumer Staples | 2.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SRCL
176
DELISTED
Stericycle Inc
SRCL
| $20M | 0.09% |
306,945
-230,059
| -43% | -$14.3M |
|
|
INVX
177
Innovex International
INVX
$1.87B
| $20M | 0.09% |
389,399
-110,570
| -22% | -$5.15M |
|
178
Illumina
ILMN
$29.4B
| $19.9M | 0.09% |
73,383
-13,373
| -15% | -$3.4M |
|
|
GSS
179
DELISTED
Golden Star Resources Ltd.
GSS
| $19.8M | 0.09% |
5,878,205
+226,867
| +4% | +$770K |
|
|
ALXN
180
DELISTED
Alexion Pharmaceuticals
ALXN
| $18.9M | 0.09% |
151,945
-20,111
| -12% | -$2.35M |
|
181
BioMarin Pharmaceuticals
BMRN
$11.5B
| $18.7M | 0.09% |
198,678
-38,734
| -16% | -$3.39M |
|
182
VEON
VEON
$3.53B
| $18.3M | 0.09% |
308,242
-16,561
| -5% | -$1.04M |
|
|
SRE.PRA
183
DELISTED
Sempra Energy 6% Mandatory Convertible Preferred Stock, Series A
SRE.PRA
| $18.3M | 0.09% |
176,968
+9,924
| +6% | +$1M |
|
184
Annaly Capital Management
NLY
$16.9B
| $18.1M | 0.08% |
440,007
+7,725
| +2% | +$322K |
|
|
CAVM
185
DELISTED
Cavium, Inc.
CAVM
| $18M | 0.08% |
208,413
+44,675
| +27% | +$3.58M |
|
186
Incyte
INCY
$23.5B
| $17.9M | 0.08% |
267,338
+44,910
| +20% | +$3.07M |
|
187
IQVIA
IQV
$34.7B
| $17.9M | 0.08% |
179,205
-23,110
| -11% | -$2.31M |
|
|
GSV
188
DELISTED
Gold Standard Ventures Corp.
GSV
| $17.7M | 0.08% |
12,994,811
-972,370
| -7% | -$1.49M |
|
|
NEE.PRR
189
DELISTED
NextEra Energy, Inc.
NEE.PRR
| $17.6M | 0.08% |
307,772
+16,840
| +6% | +$956K |
|
190
Johnson & Johnson
JNJ
$635B
| $17.5M | 0.08% |
144,573
+47,551
| +49% | +$5.93M |
|
191
Teradyne
TER
$54.8B
| $17.2M | 0.08% |
451,795
-77,442
| -15% | -$3.02M |
|
192
Guidewire Software
GWRE
$11.5B
| $17.1M | 0.08% |
192,529
-6,094
| -3% | -$539K |
|
193
Qorvo
QRVO
$7.63B
| $16.4M | 0.08% |
204,628
-7,494
| -4% | -$579K |
|
194
AbbVie
ABBV
$458B
| $16.2M | 0.08% |
174,499
+65,367
| +60% | +$6.38M |
|
|
GPL
195
DELISTED
Great Panther Mining Limited
GPL
| $16.1M | 0.08% |
1,375,994
+39,602
| +3% | +$483K |
|
196
Qiagen
QGEN
$8.53B
| $16M | 0.07% |
416,905
+66,715
| +19% | +$2.45M |
|
|
CVIA
197
DELISTED
Covia Holdings Corporation Common Stock
CVIA
| $15.9M | 0.07% |
+854,851
| New | +$18.1M |
|
198
Simon Property Group
SPG
$74.5B
| $15.9M | 0.07% |
+93,180
| New | +$14.8M |
|
199
Sociedad Química y Minera de Chile
SQM
$19.6B
| $15.8M | 0.07% |
329,712
+12,374
| +4% | +$649K |
|
200
Main Street Capital
MAIN
$4.97B
| $15.8M | 0.07% |
413,929
+21,482
| +5% | +$818K |
|
Similar funds
DAM
VanEck Associates's Q2 2018 Portfolio in Review
As of Q2 2018, VanEck Associates held 881 positions worth $21.4B, up 6.3% from $20.1B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
VanEck Associates deployed $730M of net new capital in Q2 2018, opening 137 new positions and adding to 443 existing holdings. Its largest new stake was Colgate-Palmolive: 345,613 shares worth $22.4M.
By sector, the portfolio is most concentrated in Materials at 51% of assets, down from 52% a quarter earlier, followed by Energy and Healthcare.
On the sell side, the largest reduction was Newmont, an estimated $96M trimmed.
- VanEck Associates's largest Q2 2018 buy was Colgate-Palmolive: 345,613 shares worth $22.4M.
- VanEck Associates added most to AngloGold Ashanti in Q2 2018, an estimated $259M increase.
- VanEck Associates's biggest Q2 2018 reduction was Newmont, cutting an estimated $96M.
- VanEck Associates fully exited Monsanto Co in Q2 2018, selling an estimated $109M.
- VanEck Associates's ten largest holdings make up 27% of its $21.4B portfolio in Q2 2018.
- VanEck Associates opened 137 new positions and closed 30 in Q2 2018.
- VanEck Associates's portfolio value rose 6.3% quarter-over-quarter to $21.4B.
Based on VanEck Associates's 13F filing for Q2 2018, filed 13 Aug 2018.